Idrx Stock

Idrx is a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment.

Sign up today and learn more about Idrx Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Idrx Stock

IDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care with intelligently designed precision combination therapies. IDRx is headquartered in Plymouth, Massachusetts and was founded in 2022.

Funding History

August 2022$122M

Management

Co-Founder and CEO

Ben Auspitz

Co-Founder

Alexis Borisy

Vice President, Regulatory Affairs

Shrenik Desai

Chief Development Operations Officer

Jessica Christo

Chief Product Development Officer

Vic Kadambi

Co-Founder

Robert Forrester

Co-Founder

Nicholas Lydon

Co-Founder

George Demetri

Christoph Lengauer

Christoph Lengauer

Chief Development Operations Officer

Jessica Anderson

Clinical Adviser

Steve Kelsey

Vice President, Clinical Operations

Debbie Johnson

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo